Skip to main content

Table 6 Averted cervical cancer cases and deaths based on different estimation methods

From: Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model

Number of cases and deaths in each scenario Model estimated Calculated
(based on type-specific VE) (based on 93% VE to CIN3 +   [47])
No vaccine HPV-16/18 HPV-6/11/16/18 HPV-16/18
95% Vaccine coverage
Cervical cancer cases 1370 198 300 160
(% of total cervical cancer) (100.0%) (14.4%) (21.9%) (11.7%)
Cervical cancer deaths 722 104 158 84
(% of total cervical cancer deaths) (100.0%) (14.4%) (21.9%) (11.7%)
80% Vaccine coverage
Cervical cancer cases 1370 406 489 351
(% of total cervical cancer) (100.0%) (29.6%) (35.7%) (25.6%)
Cervical cancer deaths 722 213 257 185
(% of total cervical cancer deaths) (100.0%) (29.5%) (35.6%) (25.6%)
  1. Note: HPV: human papillomavirus; CIN3+ - cervical intraepithelial neoplasia type 3; VE: vaccine efficacy.
\